CRYOPORT, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $801.00K, a 72.82% decline year-over-year.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $229.00K, a 7533.33% increase year-over-year.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.02M, a 4771.43% increase year-over-year.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.95M, a 32644.44% increase year-over-year.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $3.97M, a 42.31% increase from fiscal 2024.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.79M, a 88.58% increase from fiscal 2023.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.48M, a 27.73% decline from fiscal 2022.
- CRYOPORT, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $2.05M, a 77.23% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $801.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $229.00K 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $3.97M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $1.02M 10-Q · filed 2025-11-06 | $6.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.95M 10-Q · filed 2026-08-06 | $5.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.00K 10-Q · filed 2026-05-05 | $2.18M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.79M 10-K · filed 2026-03-05 |
| 2024-09-30 | $21.00K 10-Q · filed 2025-11-06 | $648.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $9.00K 10-Q · filed 2025-08-12 | $806.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $618.00K 10-Q · filed 2025-05-08 | $2.01M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.48M 10-K · filed 2026-03-05 |
| 2023-09-30 | $179.00K 10-Q · filed 2024-11-07 | $1.93M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $1.21M 10-Q · filed 2024-08-08 | $2.75M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $92.00K 10-Q · filed 2024-05-08 | $1.83M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $2.05M 10-K · filed 2025-03-07 |
| 2022-09-30 | $999.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $284.00K 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $313.00K 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $9.00M 10-K · filed 2024-03-13 | |
| 2021-09-30 | $2.50M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $1.90M 10-Q · filed 2022-08-04 | |
| 2016-03-31 | $10.88K 10-KT · filed 2017-03-13 | |
| 2015-03-31 | $92.61K 10-K · filed 2016-06-28 | |
| 2014-03-31 | $326.89K 10-K · filed 2015-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |